Creative Planning’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-200,189
| Closed | -$124K | – | 2149 |
|
|
2018
Q4 | $124K | Buy |
200,189
+19,900
| +11% | +$20.7K | ﹤0.01% | 1600 |
|
|
2018
Q3 | $234K | Sell |
180,289
-24
| -0% | -$37 | ﹤0.01% | 1572 |
|
|
2018
Q2 | $243K | Buy |
180,313
+60,100
| +50% | +$92.1K | ﹤0.01% | 1504 |
|
|
2018
Q1 | $174K | Buy |
120,213
+99,516
| +481% | +$208K | ﹤0.01% | 1651 |
|
|
2017
Q4 | $47K | Buy |
+20,697
| New | +$52.4K | ﹤0.01% | 1798 |
|
|
2017
Q3 | – | Sell |
-629
| Closed | -$2K | – | 4682 |
|
|
2017
Q2 | $2K | Buy |
629
+4
| +0.6% | +$13 | ﹤0.01% | 4390 |
|
|
2017
Q1 | $2K | Buy |
625
+20
| +3% | +$78 | ﹤0.01% | 4387 |
|
|
2016
Q4 | $3K | Buy |
605
+100
| +20% | +$413 | ﹤0.01% | 4224 |
|
|
2016
Q3 | $2K | Sell |
505
-62
| -11% | -$201 | ﹤0.01% | 4330 |
|
|
2016
Q2 | $1K | Hold |
567
| – | – | ﹤0.01% | 4320 |
|
|
2016
Q1 | $3K | Sell |
567
-20
| -3% | -$77 | ﹤0.01% | 3897 |
|
|
2015
Q4 | $2K | Buy |
587
+375
| +177% | +$1.73K | ﹤0.01% | 4151 |
|
|
2015
Q3 | $1K | Buy |
+212
| New | +$974 | ﹤0.01% | 4269 |
|
|
2015
Q2 | – | Sell |
-200
| Closed | -$1K | – | 4192 |
|
|
2015
Q1 | $1K | Buy |
200
+29
| +17% | +$144 | ﹤0.01% | 4174 |
|
|
2014
Q4 | $1K | Buy |
+171
| New | +$688 | ﹤0.01% | 4107 |
|
Creative Planning's AST Position: Q1 2019 in Review
Creative Planning sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 200,189 shares — an estimated $124K sold.
Creative Planning first reported a position in AST in Q4 2014 and held it in 15 quarters. The position peaked at $243K in Q2 2018. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Creative Planning reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Creative Planning sold 200,189 Asterias Biotherapeutics Inc. Series A shares in Q1 2019, an estimated $124K.
- Creative Planning first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 15 quarters.
- Creative Planning's Asterias Biotherapeutics Inc. Series A position peaked at $243K in Q2 2018.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Creative Planning's 13F filing for Q1 2019, filed 24 Apr 2019.